Sinopharm Group is a large pharmaceutical and health industry group directly under the management of SASAC. It has built a whole health industry chain which integrates R&D, manufacturing, logistics and distribution, retail chain, medical health, engineering and technical services, and professional exhibition.
The group possesses 720 subsidiaries and six listed Chinese medicine companies. In 2017, the group’s operating income was 350 billion yuan ($54.8 billion), up 10. 25 percent year-on-year.
The size, efficiency and comprehensive strength of the group always maintains the leading position in the domestic pharmaceutical industry, and it has for the fourth consecutive year been approved as the “Class A in the operation and performance assessment for leaders of central enterprises” by the State Administration and Administration of the State Council.
The group has a pharmaceutical distribution network covering 31 provinces, autonomous regions and municipalities directly under the Central Government and 30 distribution centers in line with international standards. It is a large domestic biomedical R&D and production enterprise, undertaking more than 80 percent of the national immunization planning vaccine production task. The group has established production bases and medicinal materials bases such as bio-pharmaceuticals, anesthetic psychotropic drugs, antiinfective drugs, antitumor drugs, cardio-cerebrovascular drugs, respiratory system drugs and other production bases and medicinal materials bases. It has the leading applied pharmaceutical research institutions and engineering design institutes in China. In 2010, Chinese medicine group was named national innovative enterprise.
Since 1980, the group has established 20 joint ventures with China Otsuka Pharmaceutical Co Ltd, Huarui Pharmaceutical Co, Xi'an Janssen Pharmaceutical Ltd, and Bristol-Myers Squibb Pharmaceutical Co Ltd, etc. It also established trade cooperation with more than 100 countries and regions in the world, carrying out a number of international technical cooperation, greatly accelerating the pace of internationalization.
Caring for life, attending to health is the corporate conception that Sinopharm has always been committed to.
The strong sense of social responsibility has been deep into the heart of every staff of Sinopharm.
Aiming at building an industry-leading and internationally competitive pharmaceutical and health industrial group company, Sinopharm staff has been actively carrying out their political, social and economic responsibility of a central enterprise.
Sinopharm and its member enterprises have undertaken the responsibility of medical storage and emergency supply for public health emergencies disasters and epidemics since the day of establishment.
Looking back into Chinese history, SINOPHARM staff could be found at the emergency sites of various catastrophic disasters, like Tangshan Earthquake in 1976, fighting against floods in 1998, prevention and treatment of SARS 2003, fighting against the snow storm, Sichuan Earthquake in 2008 and prevention and control of H1N1 influenza in 2009.
Address: No 20 Zhichun Road, Haidian District, Beijing